Not-for-profit to link to biopharma research

BioCrossroads said today it has formed a not-for-profit group to find ways to tie pharmaceutical research in San Diego and other biotech centers to Indiana companies and universities that that can turn the discoveries into marketable drugs.

The not-for-profit, BioCrossroadsLinx, will tap more than 40 Indiana companies that support large pharmaceutical companies and small biotech firms.

Indiana has one of few concentrations in the nation of companies focused on specialized, sophisticated contract research, contract manufacturing, logistics and other drug development services, BioCrossroads President David Johnson said in a statement.

“Indiana is home to a fast-growing sector within the life sciences industry, and we’re going to leverage our strengths to link our assets to complementary groups in other areas,” Johnson said. “Regional collaboration is a differentiating factor for us.”

BioCrossroadsLinx plans to hire a consultant in San Diego who can act as a liaison between that city’s and San Francisco’s abundant life science research organizations. The fledgling not-for-profit also will look to Boston to develop relationships.

Serving as chairman of BioCrossroadsLinx will be Charles Rutledge, vice president for research at Purdue University.

Other board members include Johnson; Dr. Kenneth Cornetta, chairman and professor of the Department of Medical and Molecular Genetics at Indiana University School of Medicine; Indiana Commerce Secretary Nathan Feltman; Dan Peterson, Cook Group vice president of industry and government affairs; Tom Snyder, president of Ivy Tech Community College; and Teresa Voors, commissioner of the Indiana Department of Workforce Development.

Please enable JavaScript to view this content.

Story Continues Below

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our updated comment policy that will govern how comments are moderated.

{{ articles_remaining }}
Free {{ article_text }} Remaining
{{ articles_remaining }}
Free {{ article_text }} Remaining Article limit resets on
{{ count_down }}